Female-specific association among I, J and K mitochondrial genetic haplogroups and cancer:A longitudinal cohort study by Luchini, Claudio et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.cancergen.2018.04.003
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Luchini, C., Nottegar, A., Vaona, A., Stubbs, B., Demurtas, J., Maggi, S., & Veronese, N. (2018). Female-specific
association among I, J and K mitochondrial genetic haplogroups and cancer: A longitudinal cohort study. Cancer
Genetics and Cytogenetics, 224-225, 29-36. https://doi.org/10.1016/j.cancergen.2018.04.003
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Female-specific association among I, J and K 
mitochondrial genetic haplogroups and 
cancer: A longitudinal cohort study 
Author links open overlay 
panelClaudioLuchinia1AlessiaNottegarb1AlbertoVaonacBrendonStubbsdefJacopoDemurtasgStefania
MaggihNicolaVeronesehi 
a 
Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 
Piazzale Scuro, 10, 37134 Verona, Italy 
b 
Department of Surgery, Section of Anatomical Pathology, San Bortolo Hospital, Vicenza, 
Italy 
c 
Primary Care Department, Azienda ULSS20 Verona, Verona, Italy 
d 
South London and Maudsley NHS FoundationTrust, Denmark Hill, London SE5 8AZ, 
United Kingdom 
e 
Institute of Psychiatry, Psychology and Neuroscience, King's College London, De 
Crespigny Park, London SE5 8 AF, United Kingdom 
f 
Faculty of Health, Social Care and Education, Anglia Ruskin University, Chelmsford, 
United Kingdom 
g 
Primary Care Department, Azienda USL Toscana Sud Est, Grosseto, Italy 
h 
National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy 
i 
Institute for clinical Research and Education in Medicine (IREM), Padova, Italy 
 
 
 
 
 
 
 
Abstract 
Recent studies highlighted the role of mitochondrial dysregulation in cancer, suggesting that the 
different mitochondrial haplogroups might play a role in tumorigenesis and risk of cancer 
development. Our aim is to investigate whether any mitochondrial haplogroups carried a significant 
higher risk of cancer development in a large prospective cohort of North American people. The 
haplogroup assignment was performed by a combination of sequencing and PCR-RFLP techniques. 
Our specific outcome of interest was the incidence of any cancer during follow-up period. Overall, 
3222 participants were included in the analysis. Women having I, J, K haplogroup reported a 
significant higher incidence of cancer compared to people with other haplogroups (p < 0.0001), 
whilst in men non association was found. In the multivariate analysis, women having I, J, K 
mitochondrial haplogroup reported a 50% increased risk of cancer (HR = 1.50; 95%CI: 1.04–2.16; 
p = 0.03). This gender-linked association may be partly explained by the role of mitochondrial 
function in female-specific (e.g. BRCA-driven) oncogenesis, but further studies are needed to better 
understand this potential correlation. Our findings may have important implications for cancer 
epidemiology and prevention. 
 
 
Introduction 
Mitochondrial genome and haplogroups 
The human mitochondrial genome consists of 16,569 base pairs encoding 37 genes and finally 13 
proteins [1]. These proteins are involved in several mechanisms important for cellular function and 
survival [1]. Similarly to nuclear DNA, also mitochondrial DNA is based on a dynamic balance and 
can undergo to frequent mutations [1], [2]. Defects in repair or recombination can lead to the 
formation of single nucleotide polymorphisms (SNPs). Clusters of these specific SNPs in the 
mitochondrial genome define the so called “mitochondrial haplogroups”. They are defined by 
unique sets of SNPs, and reflect specific ancestral populations as a result of the continuous 
accumulation of mitochondrial mutations through maternal lineages [3], [4]. 
Mitochondrial function and its potential role in tumorigenesis 
Basing also on this evolutionistic point of view, it is widely accepted that the biology of 
mitochondrial DNA may partly explain the genetic predisposition to certain medical conditions, 
probably in a similar way to the mutations of nuclear DNA [5]. Recent researches have proposed 
that the different mitochondrial haplogroups might play a role in the development of several chronic 
diseases as well as of cancer [3], [6], [7], [8], [9], [10], [11]. Indeed, since mitochondrial 
haplogroups are involved not only in mitochondria physiology, but also in cell metabolism, cells or 
tissues at high consumption of energy (such as also tumor cells) represent one of the main targets of 
mitochondrial dysfunction [12]. Difference in redox signaling as a consequence of haplogroup-
associated oxidative phosphorylation capacity has been also described, highlighting the role of 
haplogroups in influencing the mitochondrial functions [13]. Notably, modifications in the number, 
shape and function of mitochondria have been reported in different cancer types. The bioenergetic 
switch from mitochondrial oxidative phosphorylation to glycolysis has been indicated to be a 
hallmark of tumorigenesis [12]. Furthermore, retrograde signaling originating from mitochondrial 
dysfunction has been suggested to initiate crucial signaling pathways fundamental for cell growth 
[12]. 
Aim of our research 
Although several studies have already indicated potential associations among particular 
mitochondrial haplogroups and the risk of cancer development [3], [6], [7], [8], [9], [10], [11], other 
studies failed to demonstrate such association [14], [15], [16]. However, such studies were almost 
exclusively cross-sectional or case-control studies, and this may have generated a potential bias. 
Given this background, we aimed to investigate whether any mitochondrial haplogroups carried a 
significant higher risk of cancer development in a large prospective cohort of North American 
people included in the Osteoarthritis Initiative. 
Materials and methods 
Data source and subjects 
All participants in this longitudinal study were recruited as part of the ongoing, publicly and 
privately funded, multicenter Osteoarthritis Initiative (OAI study) (http://www.oai.ucsf.edu/). 
Specific datasets used are those recorded during baseline (November 2008) (V00) and those 
reporting information regarding cancer incidence until the last evaluation available (96 months; 
V10). 
Patients at high risk of knee osteoarthritis (e.g. obese, with familiarity for OA) were recruited from 
four clinical sites in the US (Baltimore, MD; Pittsburgh, PA; Pawtucket, RI; and Columbus, OH) 
between February 2004 and May 2006. All participants provided written informed consent. The 
OAI study protocol was approved by the institutional review board of the OAI Coordinating Center, 
University of California at San Francisco. 
The reliability of this cohort for our aim is based on two main considerations. The first is that no 
association is reported between osteoarthritis and any cancer types. In other words, for our aim such 
population is comparable to general population. The second is that this cohort reported data on solid 
cancers (other than skin cancer, leukemia or lymphoma), following the standardized system of the 
Charleston Comorbidity Scale, but without specifying the tumor type. However, considering that 
the contemporary conception of cancer is that of a complex genetic disease, a concept of cancer not 
of the organ but in the organ in which it arises [17], [18], also the dichotomous information cancer 
yes versus cancer no may be relevant. 
Exposure 
The haplogroup assignment was performed by a previously published method [19], which consisted 
in a combination of sequencing and PCR-RFLP techniques. The sequencing technique consisted of 
the multiplex assignment of the main 6 SNPs that contribute to the generation of the most prevalent 
Caucasian haplogroups [20] (H, V, super HV, U, K, T, J) following the single base extension (SBE) 
assay. All the mitochondrial haplogroups have been named following this nomenclature in 
agreement with those suggested by the OAI (http://www.oai.ucsf.edu/): H, U, K, J, T, V, SuperHV, 
I, W, X or Others. After that, we group these haplotypes following the classification suggested by 
MITOMAP [21] in three subgroups of the superhaplogroup N family: H, T, U, V, W, X; I, J, K; 
superHV/others (Fig. 1). 
Outcomes 
Our outcome of interest was the incidence of any cancer during follow-up period. A doctor asked 
the participants if they had any cancer (other than skin cancer, leukemia or lymphoma). This 
information was recorded during the follow-up visits number V03, V06, V08, and V10. 
Covariates 
A number of variables were identified from the OAI dataset to explore the relationship between 
mitochondrial haplogroups and incident cancer. These included: (1) physical activity evaluated 
through the Physical Activity Scale for the Elderly [22]. This scale, validated in older populations, 
covers 12 different activities, such as walking, sports, and housework, and is scored from 0 to 400 
and more; (2) smoking habits as “previous/current” versus never; (3) educational level was 
categorized as “degree” versus others; (4) yearly income as <versus≥ 50,000 $ or missing data; (5) 
co-morbidities assessed through the modified Charlson comorbidity score, with higher scores 
indicating an increased severity of conditions [23]; (7) body mass index (BMI), as recorded by a 
trained nurse; (8) depressive symptoms derived from the 20-item Center for Epidemiologic Studies-
Depression (CES-D) instrument [24]. The range of possible values for this score is 0 to 60, where 
higher scores indicate more depressive symptoms [24]. 
Statistical analyses 
Since the interaction gender by mitochondrial haplogroups, taking incident cancer as outcome, was 
significant (p < 0.0001 in the Cox's regression analysis), all the data are reported by sex. For 
continuous variables, normal distributions were tested using the Kolmogorov–Smirnov test. The 
data are shown as means and standard deviations (SD) for quantitative measures, and number with 
percentages for all discrete variables by mitochondrial haplogroups. 
For continuous variables, Analysis of Variance (ANOVA) with the Bonferroni's correction was 
used, whilst logistic regression analysis was applied for discrete variables. In all the analyses, the 
haplogroups H, T, U, V, W, X were taken as reference, being the most frequent in both sexes. 
Levene's test was used to test the homoscedasticity of variances and, if its assumption was violated, 
then Welch's ANOVA was used. 
The strength of the association of mitochondrial haplogroups and incident cancer was assessed 
through a Cox's regression analysis. Factors significantly associated with incident cancer or 
significantly different across mitochondrial haplogroups (taking a p-value < 0.05 as statistically 
significant) were included. Multi-collinearity among covariates was assessed through variance 
inflation factor, taking a cut-off of 2 as a reason of exclusion, but no variable was excluded due to 
this reason. The basic model was not adjusted for any confounders, whilst the fully adjusted model 
included baseline values of: age, BMI, Physical Activity Scale in the Elderly (PASE) score, CES-D 
score, Charlson comorbidity index as continuous variables, education, smoking habits, yearly 
income as categorical variables. Data of Cox's regression analysis were reported as hazard ratios 
(HRs) with 95% confidence intervals (CIs). 
All analyses were performed using the SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois). All 
statistical tests were two-tailed and statistical significance was assumed for a p-value < 0.05. 
Results 
Study participants 
At baseline, among 4796 potentially eligible individuals, 1047 subjects did not have a 
mitochondrial DNA assessment, 126 did not have this assessment for technical problems, 186 had 
cancer at baseline and 215 were lost at follow-up. Thus, 3222 participants were included in the 
analysis. 
Baseline analyses 
The 3222 participants included aged a mean of 61.3 ± 9.3 (range: 45–79) years, with a higher 
prevalence of women (1816 = 56.4%). All participants were Caucasians. 
The baseline characteristics of the participants by gender and mitochondrial haplogroup are shown 
in Table 1. In men, taking participants with H, T, U, V, W, X haplogroup as reference (n = 1085), 
participants with superHV/other haplogroups (n = 77) reported significant lower PASE score 
(p = 0.001) and those with I, J, K haplogroup (n = 244) a significant lower prevalence of 
previous/actual smokers (Table 1, left side). In women, no statistical differences emerged across 
mitochondrial haplogroups. 
Association between mitochondrial haplogroups and incident cancer 
After a median period of 8 years, 171 men and 169 women developed cancer equal to 10.6% of the 
baseline population. 
As reported in Fig. 2, women having I, J, K haplogroup (n = 345) reported a significant higher 
incidence of cancer compared to people with H, T, U, V, W, X haplogroup (n = 1371) and 
superHV/others (n = 100) (p < 0.0001), whilst in men non association was found (p = 0.60) (other 
details not shown). 
Using a Cox regression analysis, adjusted for eight potential confounders at baseline, with those 
having the haplogroup H, T, U, V, W, X, women having I, J, K mitochondrial haplogroup reported 
a 50% increased risk of cancer (HR = 1.50; 95%CI: 1.04–2.16; p = 0.03). In men, no significant 
association between mitochondrial haplogroups and cancer was found (Table 2). 
 
Discussion 
Female-specific association among haplogroups and risk of cancer 
The main finding of our work is represented by the fact that the 345 women having I, J, K 
haplogroup reported a significant higher incidence of cancer compared to people with H, T, U, V, 
W, X haplogroup (n = 1371) and superHV/others (n = 100) (Fig. 2). In the multivariate analysis, 
women having I, J, K mitochondrial haplogroup reported a 50% increased risk of cancer 
(HR = 1.50; 95%CI: 1.04–2.16; p = 0.03). Notably, this association was not significant in men. 
Recent works have pointed out that certain haplotypes are significantly associated with particular 
tumor types, above all female-specific tumor types (breast and gynecological cancer [11], [25], 
[26], [27], [28]), while there are no association among haplogroups and male-specific tumor types 
(prostate and testicular cancer) [14], [15], [16], [29]. Our findings may be interpreted in the light of 
these recent works, further highlighting the gender-specific role of haplogroups in influencing the 
risk of cancer development in females. It has also to be recognized that for some tumor types, there 
are no specific associations among any haplogroups and patients’ gender (e.g. lung cancer and 
gastric cancer) [30], [31]. 
For male-specific tumors, Giorgi et al. in a cohort of over 7,000 people found no association 
between any haplogroups and overall prostate cancer risk [29]. Similar findings were replicated by 
Mueller et al. [15] and also by Avarez-Cubero et al. [16] At the same time, also Ewis et al. [14] did 
not find any association between particular haplogroups and risk of testicular germ-cell tumors. 
Conversely, for female-specific cancers, other papers have recently indicated a significant 
association among specific haplogroups and risk of tumors. Li et al. have indicated a specific sub-
haplogroup, the D4b1 typical of Chinese population, as associated with cervical tumorigenesis [28]. 
Also another recent paper highlighted the role of haplogroups in cervical cancer, indicating that a 
de-regulation of mitochondrial genes may be involved in the development of such cancer [27]. Earp 
et al. furthermore, described a strong association between specific inherited common variants of 
mitochondrial DNA and serous ovarian cancer risk [25]. Several other authors, lastly, definitively 
clarified that peculiar haplogroups are associated with a specific risk of breast cancer [11], [16]. 
Potential associations among female-specific oncogenesis and haplogroups 
This gender-specific association may be partly explained by the intimate correlation between 
mitochondrial haplogroups and mutational status of BRCA (Breast Cancer) genes. Indeed, Tommasi 
et al. indicates that mitochondrial haplogroup X is the most frequent haplogroup in BRCA1-mutated 
carriers, and the haplogroup H as significantly linked to BRCA2-mutated carriers [11]. Such genes 
are known to be involved in the oncogenesis of breast and ovarian cancer, and their mutational 
status (both somatic and germline) can now be determined very accurately with next-generation 
sequencing [32]. It may be useful in the future, also on the basis of our work, to integrate the 
pathology report not only with BRCA genes or other genes (so called “next generation diagnosis” 
[33]) mutational status, but also with a characterization of mitochondrial haplogroups. Indeed, 
above all for genetic material that has a specific gender-association or a maternal inheritance (e.g. 
BRCA-associated protein gene, that is mostly mutated in females, mitochondrial haplogroups, etc.), 
there are also important implications for screening, follow-up and therapy [34], not only of patients 
but also for their relatives. Blein et al. identified mitochondrial haplogroup T1a1 as inversely 
associated with breast cancer risk in BRCA2 mutation carriers, further highlighting the relationship 
among haplogroups and BRCAness [35]. These findings have not been confirmed by Gutierrez-
Povedano et al. however, that indicated no correlation between haplogroups and BRCA genes 
mutational status [36]. Although the complex mitochondrial landscape has not been fully explained, 
our work, in which the risk of cancer is strongly associated with gender and haplogroups, seems to 
further support a possible association among mitochondrial haplogroups and mutational status of 
genes strongly associated with female-cancers. However, in our analysis, the haplogroups with the 
highest risk are I, J and K. This difference may reside in the different populations studied, involving 
our cohort North-American people and not European people as for Tommasi et al. [11], for 
example. 
Strengths and limitations of our research 
The findings of our paper should be interpreted within its limitations. First, the OAI included only 
people with or at high risk of knee osteoarthritis and so it could be not fully representative of the 
general population. However, since no association is reported between osteoarthritis and any cancer 
types, for the specific aim of cancer research this cohort is comparable to general population with a 
certain degree of reliability. Second, this cohort reported data on solid malignancies, but without 
specifying the tumor type during follow-up, and the information are self-reported. However, as 
already indicated in the Methods section, also the dichotomous information “cancer yes” versus 
“cancer no” may be relevant to assess the genetic impact of mitochondrial haplogroups on cancer 
epidemiology. The self-reported method is not an improvised system, but follows strictly the 
standardized method of the Charleston Comorbidity Scale. Moreover, the agreement between self-
reported information and registry-confirmed diagnoses is high, indicating that self-reported 
information can be used as good proxy for the real presence of cancer [37]. About the tumor-types, 
the lack of the distinction of the specific tumor-types does represent a limitation of our work. 
However, in our opinion, this study may have the merit to suggest a certain predisposition of a 
female subpopulation to cancer in general. This preliminary report calls for future studies that 
should explore more in depth not only the peculiar association among some haplogroups and cancer 
in women, but also the possible presence of a specific cancer type in this subpopulation. Third, the 
number of people in some haplogroups is limited, but to go beyond this limitation we grouped the 
haplogroups in three distinct supergroups, following the indication of MITOMAP [21]. To further 
support the reliability of this research, furthermore, we highlight as strengths of our work the length 
of follow-up (median period: 8 years), the longitudinal design, the substantial number of eight 
confounders considered in multivariate analysis, and also a significant sample size. 
Conclusions 
In conclusion, we have reported a strong association among haplogroups I, J and K and risk of 
cancer in women, highlighting the potential role of mitochondrial genetics in influencing the 
predisposition to cancer in general, and that the risk of cancer based on particular mitochondrial 
haplotypes may be relevant in female subject only. The overall message of this paper is indeed 
about cancer in general, which now should be conceived not more as a specific disease of a specific 
organ (e.g. cancer of the breast, cancer of the colon, etc.) but as a general and genetic disease in a 
specific organ (e.g. cancer in the breast, cancer in the colon, etc.) [37], [38] Also in the light of this 
observation, the predisposition of women with certain haplogroups merits and warrants 
consideration by the scientific community. Further studies are needed to completely understand the 
complex network of associations among mitochondrial haplogroups, oncogenes and gender. Future 
screening program may also taken into account the analysis of such haplogroups to address 
particular strategies of cancer prevention. 
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